

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia https://doi.org/10.1007/s00125-018-4772-2

Islet preparation	1	2	3	4	5	6	7	8ª	9	10		
MANDATORY INFORMATION												
Unique identifier	HR14	HR19	HR21	?2010?	1120	1299	SAMN12500521	DO NOT HAVE	1279	1546		
Donor age (years)	55	30	32	55	43	38	52	54	40	30		
Donor sex (M/F)	F	М	M	М	М	F	М	М	М	М		
Donor BMI (kg/m²)				37.5	36.5	44.7	29	42.8	30.7	56.8		
Donor HbA _{1c} or other measure of blood glucose control												
Origin/source of islets ^b												
Islet isolation centre	WASH U in 1997 before IIDP	WASH U in 1997 before IIDP	WASH U in 1997 before IIDP	UW MSN	UW MSN	UW MSN	UW MSN	UW MSN	UW MSN	UW MSN		
Donor history of diabetes? Please select yes/no from drop down list												
If Yes, complete the next two	o lines if this	information i	is available									
Diabetes duration (years)												
Glucose-lowering therapy at time of death ^c												

Continues on the next page

RECOMMENDED INFORMATION										
Donor cause of death										
Warm ischaemia time (h)										
Cold ischaemia time (h)				3.13	15	8.5	8.2	6.5	6.15	8
Estimated purity (%)	70	95	90	90	90	95	95	90	90	95
Estimated viability (%)				82	90	95	95	98	90	95
Total culture time (h)d										
Glucose-stimulated insulin secretion or other functional measuremente										
Handpicked to purity? Please select yes/no from drop down list										
Additional notes										

^aIf you have used more than eight islet preparations, please complete additional forms as necessary ^bFor example, IIDP, ECIT, Alberta IsletCore ^cPlease specify the therapy/therapies ^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory ^ePlease specify the test and the results